SAB Biotherapeutics Hosts U.S. Representatives Dusty Johnson and Dean Phillips for South Dakota Facility Tour
SAB Biotherapeutics (SABS) hosted Congressmen Dusty Johnson and Dean Phillips on July 1, 2022, at its Sioux Falls facility. The visit showcased SAB's innovative immunotherapy platform that produces fully human polyclonal antibodies through genetically engineered cattle. The Congressmen engaged with SAB's management team, discussing advancements in COVID-19 treatment and the company's pipeline targeting influenza, oncology, and type 1 diabetes. SAB aims to address unmet global health needs with its DiversitAb™ platform.
- SAB's technology offers scalable production of high-potency human polyclonal antibodies.
- Congressional visit highlights growing recognition and support for SAB's innovation.
- SAB has multiple ongoing drug development programs and collaborations with government and global pharmaceutical firms.
- None.
SIOUX FALLS, S.D., July 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB, or “the Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, hosted U.S. Congressmen Dusty Johnson (R-SD) and Dean Phillips (D-MN-3) on Friday, July 1, for a tour of SAB’s facilities and to learn about SAB’s innovative immunotherapy platform that enables a scalable and reliable production of polyclonal antibodies.
During their visit, Congressmen Johnson and Phillips toured SAB’s Plasma Production Facility, featuring the company’s transchromosomic (Tc) Bovine™—genetically engineered cattle—which provide SAB’s fully human polyclonal antibodies for therapeutics. The Congressmen also met with members of SAB’s management team to discuss the company’s history in COVID-19 treatment development and SAB’s current pipeline in influenza, oncology, and type 1 diabetes.
“We were pleased to host Congressmen Johnson and Phillips at SAB. We are tremendously proud of the novel immunotherapy technology we have developed here in South Dakota, and we were able to show Congressmen Johnson and Phillips our state-of-the-art Plasma Production Facility and our ability to quickly develop novel therapeutics using polyclonal antibodies,” said Eddie J. Sullivan, Ph.D., co-founder, President and Chief Executive Officer of SAB Biotherapeutics. “We greatly appreciated the Congressmen’s time in South Dakota, and it was a pleasure discussing SAB’s mission to address unmet global health needs and bring critical therapies to patients worldwide.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies with a focus on building a leading immune and autoimmune disorders pipeline. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune and autoimmune disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn.
Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of SAB-185, our influenza program and other discovery programs, our cash runway into 2023 and potential future government and third-party collaborations or funded programs.
These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB. A further description of risks and uncertainties can be found in SAB’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other periodic reports filed with the Securities and Exchange Commission, all of which will be filed with the U.S. Securities and Exchange Commission and available at https://www.sec.gov/
CONTACTS
Investor Relations:
SABIR@westwicke.com
Media Relations:
SABPR@westwicke.com
FAQ
What did SAB Biotherapeutics showcase during the Congressman visit?
Which Congressmen visited SAB Biotherapeutics on July 1, 2022?
What is the focus of SAB Biotherapeutics' drug development programs?
What is SAB Biotherapeutics' DiversitAb™ platform?
How does SAB Biotherapeutics produce its antibodies?
